Sustainability in Drug Delivery179

Issue No #179 Oct/Nov 2025 November 6th, 2025

179 - Oct/Nov 2025

Inside the magazine

CLOSING THE LOOP: DESIGNING THE FUTURE OF SUSTAINABLE DRUG DELIVERY DEVICES

CLOSING THE LOOP: DESIGNING THE FUTURE OF SUSTAINABLE DRUG DELIVERY DEVICES

Thuysi Dao outlines a two-pronged approach to improving the sustainability profile of drug delivery devices, combining sustainable device design with real-world take-back and recycling initiatives, and explores how Ypsomed’s new YpsoLoop autoinjector platform embodies this vision.

A BREATH OF FRESH AIR: PHARMA’S PUSH FOR SUSTAINABLE pMDIs

A BREATH OF FRESH AIR: PHARMA’S PUSH FOR SUSTAINABLE pMDIs

Andy Burns considers the driving factors for the transition to more sustainable propellants, as well as explaining the benefits and challenges of these next-generation propellants in terms of compatibility, performance, safety and global warming potential.

SCALING LOW-CARBON pMDI PRODUCTION WITHOUT DISRUPTING PATIENT ACCESS

SCALING LOW-CARBON pMDI PRODUCTION WITHOUT DISRUPTING PATIENT ACCESS

Simon Gardner looks at how the pharmaceutical industry is scaling up production of low-carbon pressurised metered dose inhalers to cut emissions without disrupting patient care. The article considers the challenges faced by the industry, as well as the role of CDMOs in creating sustainable, scalable solutions.

FROM PAPER TO PLANET: REVOLUTIONISING ENVIRONMENTAL RESPONSIBILITY IN PHARMA

PCI Pharma Services

FROM PAPER TO PLANET: REVOLUTIONISING ENVIRONMENTAL RESPONSIBILITY IN PHARMA

Lori Jackson and Tim Hansen look at the rise of electronic batch records and the role they play in environmental sustainability in the pharmaceutical landscape.

Interview: A Structured Approach to the Eco-Design Process

Fabien de Coninck

Interview: A Structured Approach to the Eco-Design Process

Fabien De Coninck and Bruno Morchain discuss Aptar Pharma’s eco-design philosophy with ONdrugDelivery’s Guy Furness. They cover how Aptar Pharma has implemented lifecycle assessments as a key tool to elucidate the environmental footprint of the company’s rubber components for primary packaging for injectable systems, including how they tackled the unique challenges presented by the complex, proprietary formulations involved in elastomer component design.

CIRCULAR DESIGN FOR SPRINGS AND PRESSINGS IN DRUG DELIVERY DEVICES

Bianca Plankenhorn

CIRCULAR DESIGN FOR SPRINGS AND PRESSINGS IN DRUG DELIVERY DEVICES

Bianca Plankenhorn discusses how sustainability is becoming an increasingly prominent and important part of the drug delivery industry, and how collaboration across the value chain – including steel spring and stampings manufacturers such as Lesjöfors – is critical for the industry to achieve its climate and emissions goals.

ADOPTION OF SUSTAINABILITY PRACTICES WITHIN SUBCUTANEOUS DRUG DELIVERY: INDUSTRY INSIGHTS

ADOPTION OF SUSTAINABILITY PRACTICES WITHIN SUBCUTANEOUS DRUG DELIVERY: INDUSTRY INSIGHTS

Conor O’Neill (GSK), Duncan Paterson (AstraZeneca) and Dr Monica Adams (GSK) come together to discuss a recent study conducted by the Subcutaneous Drug Development & Delivery Consortium among its member organisations, digging into the pharmaceutical industry’s progress and priorities when it comes to improving the environmental impact of subcutaneous medicines.

SUSTAINABLE DRUG DELIVERY SYSTEMS: COLLABORATIVE INNOVATION TO SHRINK PHARMA’S PACKAGING FOOTPRINT

SUSTAINABLE DRUG DELIVERY SYSTEMS: COLLABORATIVE INNOVATION TO SHRINK PHARMA’S PACKAGING FOOTPRINT

Maria Riccius and Dr Uwe Hanenberg explore how CDMOs are playing a pivotal role in driving drug delivery’s transformation towards sustainability, examining the most promising advances and highlighting why collaborative innovation is essential to achieving measurable environmental gains, both within organisations and across the pharmaceutical value chain.

SUSTAINABILITY AS STRATEGY: HOW PHARMA IS DRIVING CLIMATE INNOVATION

Dr Sofia Sotiropoulou

SUSTAINABILITY AS STRATEGY: HOW PHARMA IS DRIVING CLIMATE INNOVATION

Dr Sofia Sotiropoulou discusses the increasing emphasis that pharma companies are putting on sustainability metrics, and how they are extending this emphasis to their entire supply chains, placing expectations on design and manufacturing partners to participate in meeting sustainability targets.

Top